Michael Agrez

North Ryde, NSW, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Immune tolerance versus cancer surveillance: an ongoing challenge.

Immune tolerance versus cancer surveillance: an ongoing challenge.

Journal: Journal for immunotherapy of cancer
Published: May 07, 2026

An Immunomodulating Peptide With Potential to Counteract Endometriosis.

An Immunomodulating Peptide With Potential to Counteract Endometriosis.

Journal: The Australian & New Zealand journal of obstetrics & gynaecology
Published: July 14, 2025

An Immunomodulating Peptide with Potential to Promote Anticancer Immunity Without Compromising Immune Tolerance.

An Immunomodulating Peptide with Potential to Promote Anticancer Immunity Without Compromising Immune Tolerance.

Journal: Biomedicines
Published: June 28, 2025

A novel immunomodulating peptide with potential to complement oligodeoxynucleotide-mediated adjuvanticity in vaccination strategies.

A novel immunomodulating peptide with potential to complement oligodeoxynucleotide-mediated adjuvanticity in vaccination strategies.

Journal: Scientific reports
Published: June 27, 2024

Immune-modulating nanomedicines for enhanced drug delivery to non-small-cell lung cancer.

Immune-modulating nanomedicines for enhanced drug delivery to non-small-cell lung cancer.

Journal: Biomaterials
Published: June 11, 2024

An immunomodulating peptide with potential to suppress tumour growth and autoimmunity.

An immunomodulating peptide with potential to suppress tumour growth and autoimmunity.

Journal: Scientific reports
Published: July 06, 2023

An immunomodulating peptide to counteract solar radiation-induced immunosuppression and DNA damage.

An immunomodulating peptide to counteract solar radiation-induced immunosuppression and DNA damage.

Journal: Scientific reports
Published: November 15, 2022

A novel lipidic peptide with potential to promote balanced effector-regulatory T cell responses.

A novel lipidic peptide with potential to promote balanced effector-regulatory T cell responses.

Journal: Scientific reports
Published: December 30, 2021

Integrin αvβ6 plays a bi-directional regulation role between colon cancer cells and cancer-associated fibroblasts.

Integrin αvβ6 plays a bi-directional regulation role between colon cancer cells and cancer-associated fibroblasts.

Journal: Bioscience reports
Published: February 08, 2018

Norcantharidin Suppresses Colon Cancer Cell Epithelial-Mesenchymal Transition by Inhibiting the αvβ6-ERK-Ets1 Signaling Pathway.

Norcantharidin Suppresses Colon Cancer Cell Epithelial-Mesenchymal Transition by Inhibiting the αvβ6-ERK-Ets1 Signaling Pathway.

Journal: Scientific reports
Published: August 06, 2015

Characterization of the interaction between heterodimeric αvβ6 integrin and urokinase plasminogen activator receptor (uPAR) using functional proteomics.

Characterization of the interaction between heterodimeric αvβ6 integrin and urokinase plasminogen activator receptor (uPAR) using functional proteomics.

Journal: Journal of proteome research
Published: October 17, 2014

Integrin αvβ6 and transcriptional factor Ets-1 act as prognostic indicators in colorectal cancer.

Integrin αvβ6 and transcriptional factor Ets-1 act as prognostic indicators in colorectal cancer.

Journal: Cell & bioscience
Published: April 03, 2014
Showing 1-12 of 13

Last Updated: 09/26/2026